Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2025
Dual Immune Check Point Blockade in
Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Neoadjuvant PD1 plus CTLA-4 immune checkpoint blockade in surgically resectable recurrent glioblastoma: a randomized surgical window-of-opportunity trial.Nature communications · 2026Trial
- A phase 2, open label, clinical trial of pre-surgical and adjuvant treatment of recurrent glioblastoma with tremelimumab and durvalumab alone and in combination.Journal of neuro-oncology · 2026Trial
- Immunotherapy for Newly Diagnosed Glioblastoma: Current Evidence and Future Perspectives.Journal of personalized medicine · 2026Review
- The evolution of RTOG and NRG Oncology CNS tumors clinical trials.Journal of neuro-oncology · 2026Review
- Challenges and opportunities in combining radiotherapy and immunotherapy for localized pancreatic cancer.Nature reviews. Gastroenterology & hepatology · 2026Review
- Brain barriers at the crossroads of glioma immune surveillance and immunotherapy response.Nature reviews. Cancer · 2026Review
- GDPPH1 induces cell cycle arrest by downregulation of CDK4/Cyclin D1 via the mCell death & disease · 2026Article
- Emerging roles of ferroptosis in modulating the immune landscape of glial tumours.Nature cell biology · 2026Review
- Advances and challenges in glioblastoma immunotherapy: a meta-analysis of immune checkpoint inhibitors.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Review
- Platinum-based therapeutics as emerging multi-modal radiosensitizers in glioblastoma treatment.Advanced drug delivery reviews · 2026Review
- Reply to: Blood-Brain Barrier Heterogeneity in NRG BN007: Implications for Immunotherapy Delivery.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026Article
- Clinical, molecular, and immunologic determinants of survival in WHO-defined IDH-wildtype glioblastoma treated with radiotherapy: a large real-world cohort study.Journal of neuro-oncology · 2026Article
- Connexin-Pannexin duality in glioblastoma.Cell and tissue research · 2026Review
- Immunotherapies for Central Nervous System Tumors and their Neurologic Complications.Current neurology and neuroscience reports · 2026Review
- Current Status and Evolution of Immunotherapy in Glioma Management.International journal of medical sciences · 2026Review
- The exploration of iparomlimab and tuvonralimab combined with de-escalated chemotherapy as an innovative neoadjuvant treatment strategy for locally advanced cervical cancer: a case report from the NICE-CC trial.Frontiers in immunology · 2026Article
- Glioblastoma,Frontiers in oncology · 2026Article
- Phase II Trial Evaluating the Association of Peripheral Blood Immunologic Response to Therapeutic Response After Adjuvant Treatment with Immune Checkpoint Inhibition (ICI) in Patients with Newly Diagnosed Glioblastoma or Gliosarcoma.medRxiv : the preprint server for health sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
Abstract
purposeNew therapies for glioblastoma are needed, especially
methodsAdults with newly diagnosed u
resultsOne hundred fifty-nine participants were randomly assigned (79 immunotherapy and 80 TMZ). Arms were well balanced for age (median 60 years, range, 28-79), sex (male n = 105, 66%), KPS (90-100 n = 97, 61%), resection extent (gross total, n = 103, 65%), and RPA class (III, n = 16, 10%; IV, n = 116, 73%; V, n = 27, 17%). A preplanned analysis of phase II data conducted after 100 centrally determined PFS events showed no significant PFS improvement for ipi and nivo versus TMZ (median 7.7 months
conclusionIpi and nivo did not improve PFS among patients with newly diagnosed u
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.